to help advance the candidate into a Phase III trial for familial adenomatous polyposis (FAP). Following the 26 April announcement, Biodexa’s stock increased by 128.8%, raising the stock price ...

A free fatty acid form of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) reduces both the size and number of polyps in patients with familial adenomatous polyposis (FAP ...

Multi-target stool DNA test adherence among average-risk 45- to 49-year-old patients from 2017-2023. Refining colorectal cancer screening strategies using polygenic risk scores and classical risk ...

Patients with the inherited, autosomal-dominant disorder, familial adenomatous polyposis (FAP) characteristically develop numerous colorectal adenomas during adolescence, and suffer from ...

If conditions such as familial adenomatous polyposis, MYH-associated polyposis, or hereditary non-polyposis colorectal cancer run in your family, that raises the risk for colon cancer (and other ...

The rights come with $17M in non-dilutive funding for a pivotal Phase 3 study of the drug in the treatment of Familial Adenomatous Polyposis, or FAP, a genetic orphan disease that can cause ...

This procedure is commonly used to treat ulcerative colitis, Crohn's disease, and familial adenomatous polyposis. It is often done in a minimally invasive fashion which involves the use of small ...

The disorder has much in common with familial adenomatous polyposis among humans, so the researchers studied the adenomatous polyposis coli (APC) gene, which causes the disease. The results showed ...